Evidence map›Paper›PMID 35738906›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

The Prognostic Value of Posttreatment

Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J Martin and 3 more

Open access · bronzeAbstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Prognostic Value ofAnnals of nuclear medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. A machine learning model incorporatingQuantitative imaging in medicine and surgery · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. LuPIN Substudy of Posttreatment PET afterRadiology. Imaging cancer · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Sarennya PathmanandavelDepartment of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia; sarennya@gmail.com.
Megan CrumbakerKinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Andrew NguyenDepartment of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Andrew O YamKinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Peter WilsonMIM Software, Inc., Cleveland, Ohio.
Remy NimanMIM Software, Inc., Cleveland, Ohio.
Maria AyersDepartment of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Shikha SharmaDepartment of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Peter EuPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew J MartinNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; and.
Martin R StocklerNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; and.
Anthony M JoshuaKinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
Louise EmmettDepartment of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
St Vincent's Hospital Sydney · AUNational Health and Medical Research Council · AUGarvan Institute of Medical Research · AUPeter MacCallum Cancer Centre · AUSt Vincent's Clinic · AUSt Vincent's Hospital · AUThe Kinghorn Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantDipeptidesFluorodeoxyglucose F18Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansLutetiumMalePositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsTreatment OutcomeDipeptidesFluorodeoxyglucose F18gallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenPSMA-617Radiopharmaceuticalslutetium-PSMAmetastatic prostate cancerprognosistheranosticstherapy response

Identifiers

PMID35738906
PMCPMC9841258
OpenAlexW4283311984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.